Skip to content
value.today

Exsilio Therapeutics Inc.

🇺🇸 New York, New York, USAHealth CareFounded 2022
Total raised
$85 M
1 round on record
Latest round
$85 M
Apr 2024
First round on record
Apr 2024
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Exsilio Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2024$85 MNo. 1$50 to $250 million

Exsilio Therapeutics Inc.: Raise no. 1, Apr 2024

Investors in this round

13 investors had bought by the notice of Mar 20, 2026: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$85 M of $85 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: "Series A Convertible Preferred Stock, including underlying common shares (""Convertible Security Shares"")"
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Richard Morris · Executive Officer · Chief Financial Officer
  • Tal Zaks · Director, Executive Officer
  • Thomas Barnes · Director, Executive Officer · Chief Executive Officer/President
  • Dylan Morris · Director
  • Henry Chen · Director
  • Michal Silverberg · Director
  • Nick Olsen · Director
  • Raju Prasad · Director
  • Roy Amariglio · Director
  • Stephen Squinto · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total sales includes dollar value of converted SAFEs.”

Signed by Thomas Barnes, Chief Executive Officer/President. Source: SEC Form D and 2 amendments, newest notice filed Mar 20, 2026. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Exsilio Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2026).

    SEC Form D · Mar 2026

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Mar 2026

That is all the official record says: Exsilio Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Exsilio Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 13 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Exsilio Therapeutics Inc.
NameRoleNamed in
Richard MorrisChief Financial OfficerMar 2026
Tal ZaksExecutive officerMar 2026
Thomas BarnesChief Executive Officer/PresidentMar 2026
Anat NursellaChief Financial OfficerApr 2025
Tal Zaks, M.D., Ph.D.Executive ChairmanApr 2025
Thomas Barnes, Ph.D.CEOApr 2025
Roy AmariglioChief Executive OfficerApr 2024
Dylan MorrisDirectorMar 2026
Henry ChenDirectorMar 2026
Michal SilverbergDirectorMar 2026
Nick OlsenDirectorMar 2026
Raju PrasadDirectorMar 2026
Roy AmariglioDirectorMar 2026
Stephen SquintoDirectorMar 2026
Tal ZaksDirectorMar 2026
Thomas BarnesChief Executive Officer/PresidentMar 2026
Aaron NelsonDirectorApr 2025
Raju Prasad, Ph.D.DirectorApr 2025
Tal Zaks, M.D., Ph.D.Executive ChairmanApr 2025
Thomas Barnes, Ph.D.CEOApr 2025
Alex HardingDirectorApr 2024